Chadderton, N.; Palfi, A.; Maloney, D.M.; Carrigan, M.; Finnegan, L.K.; Hanlon, K.S.; Shortall, C.; O’Reilly, M.; Humphries, P.; Cassidy, L.;
et al. Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction. Pharmaceutics 2023, 15, 322.
https://doi.org/10.3390/pharmaceutics15020322
AMA Style
Chadderton N, Palfi A, Maloney DM, Carrigan M, Finnegan LK, Hanlon KS, Shortall C, O’Reilly M, Humphries P, Cassidy L,
et al. Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction. Pharmaceutics. 2023; 15(2):322.
https://doi.org/10.3390/pharmaceutics15020322
Chicago/Turabian Style
Chadderton, Naomi, Arpad Palfi, Daniel M. Maloney, Matthew Carrigan, Laura K. Finnegan, Killian S. Hanlon, Ciara Shortall, Mary O’Reilly, Peter Humphries, Lorraine Cassidy,
and et al. 2023. "Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction" Pharmaceutics 15, no. 2: 322.
https://doi.org/10.3390/pharmaceutics15020322
APA Style
Chadderton, N., Palfi, A., Maloney, D. M., Carrigan, M., Finnegan, L. K., Hanlon, K. S., Shortall, C., O’Reilly, M., Humphries, P., Cassidy, L., Kenna, P. F., Millington-Ward, S., & Farrar, G. J.
(2023). Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction. Pharmaceutics, 15(2), 322.
https://doi.org/10.3390/pharmaceutics15020322